Report Overview
The global LFA-based Cardiac market was valued at 3818 million in 2024 and is projected to reach US$ 5822 million by 2031, at a CAGR of 6.1% during the forecast period.
Lateral flow cardiac markers are a rapid detection tool based on lateral flow immunochromatography technology, which is used to qualitatively or quantitatively detect specific cardiac biomarkers in the blood (such as troponin I/T, myoglobin, BNP, etc.). The principle is to form a visual detection line on the test strip through antigen-antibody reaction, so as to quickly judge abnormal cardiac function or myocardial damage. This technology has the advantages of convenience, rapidity (results in 15-30 minutes), low cost, and no need for complex equipment. It is widely used in emergency, primary care, home self-testing and other scenarios.
Market drivers:
Disease demand growth:
Cardiovascular disease is the worlds leading cause of death, with a large and growing patient base. China has more than 330 million cardiovascular disease patients, and there is an urgent need for early screening and immediate diagnosis.
Acute myocardial infarction, heart failure and other acute diseases require rapid testing (such as the demand for troponin immediate testing in chest pain centers), and lateral flow technology can shorten the diagnosis time and improve prognosis.
Policy promotion:
Tiered diagnosis and treatment: Policies guide the sinking of high-quality medical resources, and primary medical institutions (such as community hospitals and township health centers) need to be equipped with POCT (point-of-care testing) equipment. Lateral flow cardiac markers are the first choice because of their simple operation and low cost.
Medical insurance coverage: Some cardiac marker tests are included in medical insurance, reducing the burden on patients and improving the accessibility of testing.
Technology iteration:
Sensitivity improvement: The application of nanomaterials (such as gold nanoparticles) improves detection sensitivity and can detect low-concentration markers (such as high-sensitivity troponin).
Multi-indicator joint detection: The same test strip realizes the joint detection of multiple markers (such as troponin + BNP + D-dimer), improving diagnostic efficiency.
Intelligence: Combined with mobile phone APP or portable reader, the results can be automatically transmitted and interpreted to reduce human errors.
Application scenario expansion:
Pre-hospital emergency: rapid screening at ambulance and emergency scene, auxiliary decision-making (such as whether to transfer directly to the catheterization room).
Home monitoring: patients with chronic heart failure can self-test BNP at home and adjust drug dosage in time.
Physical examination screening: early cardiac function assessment for high-risk groups (such as patients with hypertension and diabetes).
Market trend:
Domestic substitution: domestic companies (such as Wondfo Biotech and Mindray Biotech) have made technological breakthroughs, breaking the import monopoly and reducing costs.
Standardized development: industry standards are gradually improved, promoting the transformation of product homogeneity to differentiated competition (such as specific marker detection and personalized services).
The lateral flow cardiac marker market is driven by disease demand, policy promotion, and technological upgrading. In the future, it will continue to develop in the direction of rapidity, multi-indicators, and intelligence, and become an important tool for the diagnosis and treatment of cardiovascular diseases.
Prospect Research Reports (PRR) has surveyed the LFA-based Cardiac companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for LFA-based Cardiac, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding LFA-based Cardiac. This report contains market size and forecasts of LFA-based Cardiac in global, including the following market information:
Global LFA-based Cardiac market revenue, 2020-2025, 2026-2031, ($ millions)
Global top five LFA-based Cardiac companies in 2024 (%)
Total Market by Segment:
Global LFA-based Cardiac market, by Type, 2020-2025, 2026-2031 ($ millions)
Global LFA-based Cardiac market segment percentages, by Type, 2024 (%)
Troponin I
Troponin T
CK-MB
Myoglobin
Others
Global LFA-based Cardiac market, by Application, 2020-2025, 2026-2031 ($ millions)
Global LFA-based Cardiac market segment percentages, by Application, 2024 (%)
Laboratory Testing
Point-of-care Testing
Global LFA-based Cardiac market, by region and country, 2020-2025, 2026-2031 ($ millions)
Global LFA-based Cardiac market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies LFA-based Cardiac revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies LFA-based Cardiac revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioM?rieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
EasyDiagnosis Biomedicine
Outline of Major Chapters:
Chapter 1: Introduces the definition of LFA-based Cardiac, market overview.
Chapter 2: Global LFA-based Cardiac market size in revenue.
Chapter 3: Detailed analysis of LFA-based Cardiac company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of LFA-based Cardiac in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
